Proapoptotic protein glyceraldehyde-3-phosphate dehydrogenase: A possible site of action of antiapoptotic drugs

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 2, 2003, Pages 291-301

  Ishitani, Ryoichi ^a   Tajima, Hisao ^b   Takata, Hiroyuki ^b   Tsuchiya, Katsumi ^a   Kuwae, Toyoyasu ^a   Yamada, Mitsunori ^c   Takahashi, Hitoshi ^c   Tatton, Nadine A ^d   Katsube, Nobuo ^b  

^a JOSAI UNIVERSITY   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

^c NIIGATA UNIVERSITY   (Japan)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Aggregate formation; Antiapoptotic drugs; Apoptosis; Functional domains; Glyceraldehyde 3 phosphate dehydrogenase; Neurodegenerative disorders; Nuclear translocation; Pathogenesis; Promoter region

Indexed keywords

1 [N (4 CHLOROBENZYL)SUCCINAMOYL]PROLINAL; 10 (N METHYL N PROPARGYLAMINOMETHYL)DIBENZO[B,F]OXEPIN; ANTIPARKINSON AGENT; CHOLINESTERASE INHIBITOR; COMPLEMENTARY DNA; CYCLOHEXIMIDE; DACTINOMYCIN; DONEPEZIL; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MONOAMINE OXIDASE INHIBITOR; N (2 HEPTYL) N METHYLPROPARGYLAMINE; NOOTROPIC AGENT; RASAGILINE; SELEGILINE; TACRINE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; CELL ACTIVITY; CLINICAL TRIAL; DEGENERATIVE DISEASE; GENE CONTROL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MOLECULAR BIOLOGY; MOLECULAR CLONING; NONHUMAN; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0345268748     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00024-1     Document Type: Review

References (89)

1. Bartus R.T., Dean R.L. III, Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-417.
2. 4A binding protein. Biochemistry. 34:1995;9700-9707.
3. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 292:2001;1552-1555.
4. Berry M.D. R-2HMP, an orally active agent combining independent anti-apoptotic and MAO-B inhibitory activities. CNS Drug Rev. 5:1999;105-124.
5. Bootsma D., Ruddle F.H. Report of the committee on the genetic constitution of chromosomes 2, 3, 4, 5, 7, 8, 10, 11, and 12. Cytogenet. Cell Genet. 22:1978;74-91.
6. Boulton A.A., Davis B.A., Durden D.A., Dyck L.E., Juorio A.V., Li X.-M., Paterson I.A., Yu P.H. Aliphatic propargylamines - new antiapoptotic drugs. Drug Dev. Res. 42:1997;150-156.
7. Breteler M.M.B. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol. Aging. 21:2000;153-160.
8. Burke J.R., Enghild J.J., Martin M.E., Jou Y.-S., Myers R.M., Roses A.D., Vance J.M., Strittmatter W.J. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat. Med. 2:1996;347-350.
9. Carlile G.W., Tatton W.G., Borden K.L.B. Demonstration of a RNA-dependent nuclear interaction between the promyelocytic leukaemia protein and glyceraldehyde-3-phosphate dehydrogenase. Biochem. J. 335:1998;691-696.
10. Carlile G.W., Chalmers-Redman R.M.E., Tatton N.A., Pong A., Borden K.L.B., Tatton W.G. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol. Pharmacol. 57:2000;2-12.
11. Caswell A.H., Corbett A.M. Interaction of glyceraldehyde-3-phosphate dehydrogenase with isolated microsomal subfractions of skeletal muscle. J. Biol. Chem. 260:1985;6892-6898.
12. Chen R.-W., Saunders P.A., Wei H., Li Z., Seth P., Chuang D.-M. Involvement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and p53 in neuronal apoptosis: evidence that GAPDH is up-regulated by p53. J. Neurosci. 19:1999;9654-9662.
13. Conti E., Uy M., Leighton L., Blobel G., Kuriyan J. Crystallographic analysis of the recognition of a nuclear localization signal by the nuclear import factor karyopherin α Cell. 94:1998;193-204.
14. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 90:1997;537-548.
15. Davies S.W., Beardsall K., Turmaine M., DiFiglia M., Aronin N., Bates G.P. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? Lancet. 351:1998;131-133.
16. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 277:1997;1990-1993.
17. Ferrigno P., Silver P.A. Polyglutamine expansions: proteolysis, chaperones, and the dangers of promiscuity. Neuron. 26:2000;9-12.
18. Fort Ph., Marty L., Piechaczyk M., El Sabrouty S., Dani Ch. , Jeanteur Ph. , Blanchard J.M. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res. 13:1985;1431-1442.
19. Freeman S.E., Dawson R.M. Tacrine: a pharmacological review. Prog. Neurobiol. 36:1991;257-277.
20. +-induced apoptosis. NeuroReport. 12:2001;2049-2052.
21. Fukuhara Y., Takeshima T., Kashiwaya Y., Mishima K., Ishitani R., Nakashima K. GAPDH antisense oligonucleotide protects dopaminergic neuronal death occurring with exposure of the cerebrospinal fluid from PD patients. Soc. Neurosci. Abstr. 27:2001;198.17.
22. Goodrich J.A., Cutler G., Tjian R. Contacts in context: promoter specificity and macromolecular interactions in transcription. Cell. 84:1996;825-830.
23. Gunawardena S., Goldstein L.S.B. Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron. 32:2001;389-401.
24. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20:1997;154-159.
25. Hardy J., Gwinn-Hardy K. Genetic classification of primary neurodegenerative disease. Science. 282:1998;1075-1079.
26. Hashimoto M., Masliah E. Alpha-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol. 9:1999;707-720.
27. Igarashi S., Koide R., Shimohata T., Yamada M., Hayashi Y., Takano H., Date H., Oyake M., Sato T., Sato A., Egawa S., Ikeuchi T., Tanaka H., Nakano R., Tanaka K., Hozumi I., Inuzuka T., Takahashi H., Tsuji S. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat. Genet. 18:1998;111-117.
28. Ishitani R., Chuang D.-M. Glyceraldehyde-3-phosphate dehydrogenase antisense oligodeoxynucleotides protect against cytosine arabinonucleoside-induced apoptosis in cultured cerebellar neurons. Proc. Natl. Acad. Sci. U.S.A. 93:1996;9937-9941.
29. Ishitani R., Sunaga K., Hirano A., Saunders P., Katsube N., Chuang D.-M. Evidence that glyceraldehyde-3-phosphate dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture. J. Neurochem. 66:1996;928-935.
30. Ishitani R., Kimura M., Sunaga K., Katsube N., Tanaka M., Chuang D.-M. An antisense oligodeoxynucleotide to glyceraldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. J. Pharmacol. Exp. Ther. 278:1996;447-454.
31. +-induced apoptosis but not necrosis of cultured cerebellar granule cells. Mol. Pharmacol. 51:1997;542-550.
32. Ishitani R., Tanaka M., Sunaga K., Katsube N., Chuang D.-M. Nuclear localization of overexpressed glyceraldehyde-3-phosphate dehydrogenase in cultured cerebellar neurons undergoing apoptosis. Mol. Pharmacol. 53:1998;701-707.
33. Ishitani R., Fushiki S., Tatton N.A., Tsuchiya K., Kuwae T., Yamada M., Takahashi H., Tajima H., Katsube N. Pro-apoptotic GAPDH protein: implications in the pathogenesis of neurodegenerative disorders. Soc. Neurosci. Abstr. 27:2001;426.15.
34. Jans D.A. Nuclear signaling pathways for polypeptide ligands and their membrane receptors? FASEB J. 8:1994;841-847.
35. Katsube N., Ishitani R. A review of the neurotrophic and neuroprotective properties of ONO-1603: comparison with those of tetrahydroaminoacridine, an antidementia drug. CNS Drug Rev. 6:2000;21-34.
36. Katsube N., Maegawa H., Kagamiishi Y., Yamamoto M., Aishita H. ONO-1603 inhibits brain prolyl oligopeptidase in vitro, in vivo and in situ. Soc. Neurosci. Abstr. 20:1994;471.15.
37. Katsube N., Sunaga K., Aishita H., Chuang D.-M., Ishitani R. ONO-1603, a potential antidementia drug, delays age-induced apoptosis and suppresses overexpression of glyceraldehyde-3-phosphate dehydrogenase in cultured central nervous system neurons. J. Pharmacol. Exp. Ther. 288:1999;6-13.
38. Kim T.-W., Tanzi R.E. Neuronal intranuclear inclusions in polyglutamine diseases: nuclear weapons or nuclear fallout? Neuron. 21:1998;657-659.
39. Kish S.J., Lopes-Cendes I., Guttman M., Furukawa Y., Pandolfo M., Rouleau G.A., Ross B.M., Nance M., Schut L., Ang L., Distefano L. Brain glyceraldehyde-3-phosphate dehydrogenase activity in human trinucleotide repeat disorders. Arch. Neurol. 55:1998;1299-1304.
40. Klement I.A., Skinner P.J., Kaytor M.D., Yi H., Hersch S.M., Clark H.B., Zoghbi H.Y., Orr H.T. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell. 95:1998;41-53.
41. Koide R., Kobayashi S., Shimohata T., Ikeuchi T., Maruyama M., Saito M., Yamada M., Takahashi H., Tsuji S. A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? Hum. Mol. Genet. 8:1999;2047-2053.
42. Koshy B., Matilla T., Burright E.N., Merry D.E., Fischbeck K.H., Orr H.T., Zoghbi H.Y. Spinocerebellar ataxia type-1 and spinobulbar muscular atrophy gene products interact with glyceraldehyde-3-phosphate dehydrogenase. Hum. Mol. Genet. 5:1996;1311-1318.
43. Kragten E., Lalande I., Zimmermann K., Roggo S., Schindler P., Müller D., Van Oostrum J., Waldmeier P., Fürst P. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J. Biol. Chem. 273:1998;5821-5828.
44. Kuwae T., Yamada M., Takahashi H., Tsuchiya K., Tajima H., Katsube N., Ishitani R. Pro-apoptotic protein GAPDH: a possible site of action of anti-dementia drugs. Soc. Neurosci. Abstr. 28:2002;884.4.
45. Maruyama W., Akao Y., Youdim M.B.H., Davis B.A., Naoi M. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J. Neurochem. 78:2001;727-735.
46. Mattson M.P. Apoptosis in neurodegenerative disorders. Nature Rev., Mol. Cell Biol. 1:2000;120-129.
47. Meyer-Siegler K., Mauro D.J., Seal G., Wurzer J., Deriel J.K., Sirover M.A. A human nuclear uracil DNA glycosylase is the 37-kDa subunit of glyceraldehyde-3-phosphate dehydrogenase. Proc. Natl. Acad. Sci. U.S.A. 88:1991;8460-8464.
48. Mittag T.W., Tatton N.A., Wax M., Edward D., Chalmers-Redman R.M.E., Tatton W.G. Increased retinal ganglion cell (RGC) GAPDH, Bax and activated caspase 3 in a rat glaucoma model and in human glaucoma. Association for Research in Vision and Ophthalmology Annual Meeting:2001;. Abstr. B472.
49. Morgenegg G., Winkler G.C., Hübscher U., Heizmann C.W., Mous J., Kuenzle C.C. Glyceraldehyde-3-phosphate dehydrogenase is a nonhistone protein and a possible activator of transcription in neurons. J. Neurochem. 47:1986;54-62.
50. Moulder K.L., Onodera O., Burke J.R., Strittmatter W.J., Johnson E.M. Jr. Generation of neuronal intranuclear inclusions by polyglutamine-GFP: analysis of inclusion clearance and toxicity as a function of polyglutamine length. J. Neurosci. 19:1999;705-715.
51. Nakamura K., Jeong S.Y., Uchihara T., Anno M., Nagashima K., Nagashima T., Ikeda S., Tsuji S., Kanazawa I. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum. Mol. Genet. 10:2001;1441-1448.
52. Nucifora F.C. Jr., Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V.L., Dawson T.M., Ross C.A. Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science. 291:2001;2423-2428.
53. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22:1999;123-144.
54. Oppenheim R.W. Cell death during development of the nervous system. Annu. Rev. Neurosci. 14:1991;453-501.
55. Paterson I.A., Zhang D., Warrington R.C., Boulton A.A. R-deprenyl and R-2-heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium. J. Neurochem. 70:1998;515-523.
56. Paulson H.L., Perez M.K., Trottier Y., Trojanowski J.Q., Subramony S.H., Das S.S., Vig P., Mandel J.-L., Fischbeck K.H., Pittman N. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron. 19:1997;333-344.
57. Perutz M.F. Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem. Sci. 24:1999;58-63.
58. Piechaczyk M., Blanchard J.M., Riaad-El Sabouty S., Dani C., Marty L., Jeanteur P. Unusual abundance of vertebrate 3-phosphate dehydrogenase pseudogenes. Nature. 312:1984;469-471.
59. Portera-Cailliau C., Hedreen J.C., Price D.L., Koliatsos V.E. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci. 15:1995;3775-3787.
60. Quignon F., De Bels F., Koken M., Feunteun J., Ameisen J.-C., De Thé H. PML induces a novel caspase-independent death process. Nat. Genet. 20:1998;259-265.
61. Rathmell J.C., Thompson C.B. The central effectors of cell death in the immune system. Annu. Rev. Immunol. 17:1999;781-828.
62. Robbins A.R., Ward R.D., Oliver C. A mutation in glyceraldehyde-3-phosphate dehydrogenase alters endocytosis in CHO cells. J. Cell Biol. 130:1995;1093-1104.
63. Rogers S.L., Friedhoff L.T. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 7:1996;293-303.
64. Saudou F., Finkbeiner S., Devys D., Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 95:1998;55-66.
65. Saunders P.A., Chalecka-Franaszek E., Chuang D.-M. Subcellular distribution of glyceraldehyde-3-phosphate dehydrogenase in cerebellar granule cells undergoing cytosine arabinoside-induced apoptosis. J. Neurochem. 69:1997;1820-1828.
66. Saunders P.A., Chen R.-W., Chuang D.-M. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase isoforms during neuronal apoptosis. J. Neurochem. 72:1999;925-932.
67. Sawa A., Khan A.A., Hester L.D., Snyder S.H. Glyceraldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and nonneuronal cell death. Proc. Natl. Acad. Sci. U.S.A. 94:1997;11669-11674.
68. Schulze H., Schuler A., Stüber D., Döbeli H., Langen H., Huber G. Rat brain glyceraldehyde-3-phosphate dehydrogenase interacts with the recombinant cytoplasmic domain of Alzheimer's β-amyloid precursor protein. J. Neurochem. 60:1993;1915-1922.
69. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:2001;741-766.
70. Shashidharan P., Chalmers-Redman R.M.E., Carlile G.W., Rodic V., Gurvich N., Yuen T., Tatton W.G., Sealfon S.C. Nuclear translocation of GAPDH-GFP fusion protein during apoptosis. NeuroReport. 10:1999;1149-1153.
71. Sherman M.Y., Goldberg A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron. 29:2001;15-32.
72. Singh R., Green M.R. Sequence-specific binding of transfer RNA by glyceraldehyde-3-phosphate dehydrogenase. Science. 259:1993;365-368.
73. Sirover M.A. New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochim. Biophys. Acta. 1432:1999;159-184.
74. Sisodia S.S. Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental, or beneficial? Cell. 95:1998;1-4.
75. Suh Y.-H. An etiological role of amyloidogenic carboxyl-terminal fragments of the β-amyloid precursor protein in Alzheimer's disease. J. Neurochem. 68:1997;1781-1791.
76. Summers W.K., Majovski L.V., Marsch G.M., Tachiki K., Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N. Engl. J. Med. 315:1986;1241-1245.
77. Sunaga K., Takahashi H., Chuang D.-M., Ishitani R. Glyceraldehyde-3-phosphate dehydrogenase is over-expressed during apoptotic death of neuronal cultures and is recognized by a monoclonal antibody against amyloid plaques from Alzheimer's brain. Neurosci. Lett. 200:1995;133-136.
78. Tabrizi S.J., Cleeter M.W., Xuereb J., Taanman J.W., Cooper J.M., Schapira A.H.V. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 45:1999;25-32.
79. Tajima H., Tsuchiya K., Yamada M., Kondo K., Katsube N., Ishitani R. Over-expression of GAPDH induces apoptosis in COS-7 cells transfected with cloned GAPDH cDNAs. NeuroReport. 10:1999;2029-2033.
80. Tajima H., Tsuchiya K., Yamada M., Takata H., Katsube N., Ishitani R. Overexpression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) induces apoptosis: generation of inclusion bodies by GAPDH-GFP fusion protein. Soc. Neurosci. Abstr. 25:1999;906.11.
81. Tanaka R., Mochizuki H., Suzuki A., Katsube N., Ishitani R., Mizuno Y., Urabe T. Induction of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in rat brain after focal ischemia/reperfusion. J. Cereb. Blood Flow Metab. 22:2002;280-288.
82. Tatton N.A. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol. 166:2000;29-43.
83. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science. 267:1995;1456-1462.
84. Tso J.Y., Sun X.-H., Kao T.-H., Reece K.S., Wu R. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. Nucleic Acids Res. 13:1985;2485-2502.
85. Tsuchiya K., Tajima H., Sunaga K., Katsube N., Ishitani R. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene: two upstream regions mediate its overexpression during cytosine arabinonucleoside-induced neuronal apoptosis. Soc. Neurosci. Abstr. 26:2000;225.12.
86. West A., Farrer M., Petrucelli L., Cookson M., Lockhart P., Hardy J. Identification and characterization of the human parkin gene promoter. J. Neurochem. 78:2001;1146-1152.
87. Wilk S. Prolyl endopeptidase. Life Sci. 33:1983;2149-2157.
88. Willems P.J. Dynamic mutations hit double figures. Nat. Genet. News Views. 8:1994;213-215.
89. Zager E.L., Black P.M. Neuropeptides in human memory and learning processes. Neurosurgery. 17:1985;355-369.